Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
DAMICO JENNIFER B. | SVP & Controller | Mar 15 | Sale | 40.02 | 9,912 | 396,678 | 9,003 | Mar 17 04:53 PM | SUSMAN SALLY | Executive Vice President | Feb 25 | Option Exercise | 22.89 | 72,984 | 1,670,604 | 209,179 | Feb 28 05:52 PM | JOHNSON RADY A | Executive Vice President | Feb 25 | Option Exercise | 22.89 | 33,654 | 770,340 | 116,473 | Feb 28 05:52 PM | Hwang Angela | President, Global Biopharma | Feb 25 | Option Exercise | 22.89 | 20,273 | 464,049 | 44,541 | Feb 28 05:52 PM | McDermott Michael | Executive Vice President | Feb 25 | Option Exercise | 22.89 | 14,178 | 324,534 | 93,099 | Feb 28 05:52 PM | DAMICO JENNIFER B. | SVP & Controller | Feb 25 | Option Exercise | 22.89 | 11,150 | 255,224 | 27,893 | Feb 28 05:52 PM | SUSMAN SALLY | Executive Vice President | Feb 22 | Option Exercise | 30.17 | 76,043 | 2,294,217 | 195,493 | Feb 24 09:17 PM | Hwang Angela | President, Global Biopharmaceu | Feb 22 | Option Exercise | 30.17 | 57,032 | 1,720,655 | 67,027 | Feb 24 09:34 PM | JOHNSON RADY A | Executive Vice President | Feb 22 | Option Exercise | 30.17 | 31,558 | 952,105 | 106,556 | Feb 24 08:27 PM | SAHNI PAYAL | Executive Vice President | Feb 22 | Option Exercise | 30.17 | 15,209 | 458,856 | 32,671 | Feb 24 09:03 PM | McDermott Michael | Executive Vice President | Feb 22 | Option Exercise | 30.17 | 13,307 | 401,472 | 88,957 | Feb 24 08:52 PM | DAMICO JENNIFER B. | SVP & Controller | Feb 22 | Option Exercise | 30.17 | 10,456 | 315,458 | 21,584 | Feb 24 08:14 PM | BOURLA ALBERT | Chairman & CEO | Dec 16 | Option Exercise | 27.25 | 222,328 | 6,058,580 | 411,890 | Dec 16 06:14 PM | LANKLER DOUGLAS M | Executive Vice President | Dec 14 | Option Exercise | 26.29 | 101,658 | 2,672,548 | 180,461 | Dec 16 06:14 PM | Dolsten Mikael | President R&D | Nov 07 | Option Exercise | 33.21 | 79,108 | 2,627,260 | 420,007 | Nov 09 04:08 PM | DAMICO JENNIFER B. | SVP & Controller | Jun 07 | Sale | 53.96 | 4,218 | 227,603 | 10,846 | Jun 08 04:43 PM | DAMICO JENNIFER B. | SVP & Controller | May 16 | Sale | 50.50 | 4,000 | 202,000 | 15,064 | May 17 07:48 AM | SAHNI PAYAL | Executive Vice President | May 13 | Sale | 49.84 | 1,408 | 70,175 | 17,372 | May 16 09:23 PM | LANKLER DOUGLAS M | Executive Vice President | May 12 | Sale | 49.41 | 38,273 | 1,891,069 | 78,803 | May 13 05:19 PM | Carapezzi William R JR | Executive Vice President | May 12 | Sale | 50.00 | 32,908 | 1,645,400 | 38,146 | May 13 05:38 PM | Dolsten Mikael | President R&D | May 11 | Sale | 49.32 | 63,902 | 3,151,547 | 333,342 | May 12 04:34 PM |
|